David Kerr

CBE FMedSci FRCP

Professor of Cancer Medicine

Consultant Physician

Genetics and Genomics

In collaboration with Dr Rachel Midgley, Oncology Clinical Trials Office, we have conducted a series of international adjuvant trials of chemotherapy for colorectal cancer. In parallel, we have established a biorepository of tissue and constitutional DNA (n=3500) which has allowed us to collaborate with Ian Tomlinson to generate a number of cancer susceptibility SNPs and commercial partners to characterise a prognostic mRNA signature which assists in selection of patients for chemotherapy. We are currently developing biomarkers for the anti-angiogenic agent bevacizumab.

Key publications

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article

Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557

Recent publications

Personalising cancer medicine with prognostic markers.
Journal article

Kerr DJ. and Yang L., (2021), EBioMedicine, 72
Automated assessment of CD8+ T-lymphocytes and stroma fractions complement conventional staging of colorectal cancer.
Journal article

Jiang D. et al, (2021), EBioMedicine, 71
Novel therapeutic strategies: targeting epithelial-mesenchymal transition in colorectal cancer.
Journal article

Zhang N. et al, (2021), Lancet Oncol, 22, e358 - e368
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma.
Journal article

Booth SW. et al, (2021), BMC Cancer, 21
Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
Journal article

Watts K. et al, (2021), Int J Cancer

More publications